SCHEMBL1269153

SCHEMBL1269153

CCN(CC)N1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GFER P55789 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635558 0.97
SCHEMBL8718542 0.91
Hydrochloric Acid SCHEMBL23174550 0.88
SCHEMBL4231793 0.85 HRH3 (0.32)
SCHEMBL3985738 0.84
SCHEMBL4720625 0.81
SCHEMBL4721344 0.81 L3MBTL1 (0.34) MEN1KMT2A
SCHEMBL1206197 0.78 HRH3 (0.33) MEN1KMT2A
SCHEMBL4765150 0.78 L3MBTL1 (0.32) MEN1KMT2A
SCHEMBL16099104 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234284-A1 Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors NOVARTIS AG (CH) 2008-09-25 US claimed
EP-1910368-A1 PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2008-04-16 EP claimed
EP-1765877-A4 RADIATION-CURABLE COATINGS FOR WOOD SUBSTRATES FROM MULTIFUNCTIONAL ACRYLATE OLIGOMERS ASHLAND LICENSING & INTELLECTU (US) 2007-08-29 EP claimed
EP-1765877-A2 RADIATION-CURABLE COATINGS FOR WOOD SUBSTRATES FROM MULTIFUNCTIONAL ACRYLATE OLIGOMERS Ashland Licensing and Intellectual Property LLC (US) 2007-03-28 EP claimed
WO-2007009773-A1 PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2007-01-25 WO claimed
WO-2005111105-A2 RADIATION-CURABLE COATINGS FOR WOOD SUBSTRATES FROM MULTIFUNCTIONAL ACRYLATE OLIGOMERS ASHLAND LICENSING AND INTELLECTUAL PROPERTY LLC (US) 2005-11-24 WO claimed
US-20050245636-A1 Radiation-curable coatings for wood substrates from multifunctional acrylate oligomers ASHLAND INC. (US) 2005-11-03 US claimed
JP-63057585-A None JP disclosed
US-10258603-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-04-16 US disclosed
EP-1329975-B1 NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY CELL AND NON-AQUEOUS LIQUID ELECTROLYTE ELECTRIC DOUBLE LAYER CAPACITOR BRIDGESTONE CORP (JP) 2018-04-25 EP disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
EP-3218376-A1 BROMODOMAIN INHIBITORS AND USES THEREOF Genentech, Inc. (US) 2017-09-20 EP disclosed
EP-2927228-B1 Novel physiologically active substances EISAI R&D MAN CO LTD (JP) 2016-09-07 EP disclosed
US-20060009439-A1 Novel physiologically active substances MERCIAN CORPORATION (JP) 2006-01-12 US disclosed
US-20050245514-A1 Novel physiologically active substances MICROBIOPHARM JAPAN CO., LTD. (JP) 2005-11-03 US disclosed
EP-1548121-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2005-06-29 EP disclosed
EP-1541570-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE MERCIAN CORPORATION (JP) 2005-06-15 EP disclosed
EP-1508570-A1 NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2005-02-23 EP disclosed
WO-1995015955-A1 2,4-DIAMINOTHIAZOLES AND THEIR PRODUCTION BASF AKTIENGESELLSCHAFT (DE) 1995-06-15 WO disclosed
JP-S6357585-A ISOQUINOLINE DERIVATIVE MITSUI TOATSU CHEM INC 1988-03-12 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245514-A1 Novel physiologically active substances HIF1A, HIF1AN, VEGFA KDM4E 4239/4885MEN1 2091/4885ALDH1A1 133/4885
US-20060009439-A1 Novel physiologically active substances HIF1A, HIF1AN, VEGFA KDM4E 3533/4885MEN1 2851/4885ALDH1A1 108/4885
US-20080234284-A1 Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors MAP3K5, MAP3K20, MAP3K7 KDM4E 1865/4885MEN1 2127/4885ALDH1A1 2533/4885
US-10258603-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRD3 KDM4E 320/4885MEN1 1364/4885ALDH1A1 1563/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 KDM4E 320/4885MEN1 1364/4885ALDH1A1 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.